UCLA-CDU CFAR
加州大学洛杉矶分校-CDU CFAR
基本信息
- 批准号:10458369
- 负责人:
- 金额:$ 300.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-08 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:AIDS preventionAIDS/HIV problemAccreditationAcquired Immunodeficiency SyndromeAddressAnimal ModelAreaAwardBehavioralBiological AssayCaliforniaClinicClinicalClinical InformaticsClinical Laboratory Improvement AmendmentsClinical ResearchClinical SciencesClinics and HospitalsCollaborationsCommunitiesCountyDataDevelopmentDiseaseDisease remissionEnsureEpidemicEquipmentFacultyFundingGoalsGrantHIVHIV InfectionsHealthcare SystemsIncubatorsInfection preventionInfrastructureInstitutesInstitutionInterdisciplinary StudyLaboratoriesLeadershipLinkLos AngelesMedical centerMentorsMissionMorbidity - disease rateNeighborhoodsParticipantPathogenesisPersonsPilot ProjectsPoliciesPopulationProceduresProviderPublic Health InformaticsRegistriesRegulationResearchResearch ActivityResearch PersonnelResourcesSamplingScienceScientistServicesShapesSiteStructureTalentsTechniquesTrainingTraining ActivityTranslational ResearchUnited States National Institutes of HealthUniversitiesUrsidae Familybasebehavioral studybiobankcareercommunity based participatory researchcommunity based researchcommunity engagementcost effectivedesigngene therapyhealth equityhumanized mousemeetingsmembermetropolitanmultidisciplinarynext generationpreventprogramsrecruitresearch studysocialsubstance usesuccesssymposiumworking group
项目摘要
Overall: Project Summary/Abstract: This application is a resubmission for a new CFAR that is a partnership
between UCLA and CDU. Our overarching goal is to create a nimble multi-institutional infrastructure that
promotes equity and will connect and support investigators affiliated with both institutions to advance critical HIV
science. The UCLA-CDU CFAR will strengthen and amplify the impact of existing research activities and launch
new partnerships across Los Angeles and globally through our focus on three themes: we will STOP HIV by
preventing new HIV infections (Prevention), reducing morbidity among people living with HIV (Treatment) and
developing strategies for eradication (ART-free Remission). This grant will fund AIDS-related activities and
programs conducted by investigators at UCLA, CDU and our Affiliated institutions, which include Harbor-UCLA
Medical Center in Torrance; the UCLA CARE Clinic and the VA Greater Los Angeles Healthcare System in
Westwood; the UCLA Vine Street Clinic in West Hollywood; and the Drew CARES, the CDU PUSH coalition and
the MLK OASIS Clinic at CDU. These facilities are at ground zero for the AIDS epidemic in Los Angeles County,
with the greatest number of persons living with HIV residing in the neighborhoods directly served by our hospitals
and clinics. In addition to the facilities and programs based in Los Angeles, researchers at UCLA and CDU have
extensive partnerships with HIV programs around the globe that are aimed at building global capacity. The CFAR
will enhance our ability to deliver research at the interface of community by reaching communities most in need
and by bringing to bear the talent of CDU and UCLA researchers to address problems from a multi-disciplinary
perspective while mentoring the next generation who better reflect the diversity of communities being served.
The overall organization of the UCLA-CDU CFAR will allow us to efficiently and effectively manage AIDS
research activities by harnessing the diverse expertise in our CFAR, and by including linkages to community-
based clinician investigators and communities. The action plan for the first year of requested support includes
6 cores and 1 scientific working group (SWG): the Administrative Core, Developmental Core, Centralized
Laboratory Support Core, Humanized Mouse and Gene Therapy Core, Community Engagement and Clinical
Informatics Core, Clinical Science Core, and a Translational Research in Substance Use SWG. RELEVANCE:
Research into the pathogenesis, treatment and social aspects of HIV disease is required to end the epidemic.
The UCLA-CDU CFAR seeks to catalyze and expand HIV research by providing the infrastructure to connect,
support and enhance the capacity of investigators affiliated with UCLA and CDU. This will be accomplished by
stimulating the conduct and dissemination of high impact multidisciplinary research aimed at the NIH priorities
of preventing new HIV infections (Prevention), reducing morbidity among people living with HIV (Treatment) and
developing strategies for eradication (ART-free Remission).
总体:项目摘要/摘要:此应用程序是一个新的CFAR是一个合作伙伴关系的重新提交
加州大学洛杉矶分校和基督教民主联盟之间我们的首要目标是建立一个灵活的多机构基础设施,
促进公平,并将连接和支持与这两个机构有关联的调查人员,以推动关键的艾滋病毒
科学UCLA-CDU CFAR将加强和扩大现有研究活动的影响,并启动
通过我们对三个主题的关注,在洛杉矶和全球范围内建立新的伙伴关系:我们将通过
预防新的艾滋病毒感染(预防),降低艾滋病毒感染者的发病率(治疗),
制定根除战略(无抗逆转录病毒疗法缓解)。这笔赠款将资助与艾滋病有关的活动,
由加州大学洛杉矶分校,基民盟和我们的附属机构,其中包括港口,加州大学洛杉矶分校的研究人员进行的计划,
托兰斯医疗中心;加州大学洛杉矶分校护理诊所和弗吉尼亚州大洛杉矶医疗保健系统,
韦斯特伍德;西好莱坞的加州大学洛杉矶分校藤街诊所;德鲁关怀,基民盟推动联盟和
基督教民主联盟的MLK绿洲诊所这些设施是洛杉矶县艾滋病流行的起点,
居住在我们医院直接服务的社区的艾滋病毒感染者人数最多
和诊所。除了位于洛杉矶的设施和项目外,加州大学洛杉矶分校和基民盟的研究人员还
与地球仪各地旨在建设全球能力的艾滋病毒方案建立广泛的伙伴关系。恒虚警
将通过接触最需要的社区,提高我们在社区界面提供研究的能力
并通过发挥CDU和UCLA研究人员的才能,
在指导下一代更好地反映所服务社区的多样性的同时,
加州大学洛杉矶分校-基民盟CFAR的整体组织将使我们能够有效地管理艾滋病
研究活动,通过利用我们的CFAR中的各种专业知识,并包括与社区的联系,
基于临床研究者和社区。第一年所请求支助的行动计划包括
6个核心和1个科学工作组(SWG):行政核心、发展核心、中央
实验室支持核心,人源化小鼠和基因治疗核心,社区参与和临床
信息学核心,临床科学核心和物质使用转化研究SWG。相关性:
需要研究艾滋病毒疾病的发病机理、治疗和社会方面,以结束这一流行病。
UCLA-CDU CFAR旨在通过提供连接,
支持和提高隶属于加州大学洛杉矶分校和基督教民主联盟的调查人员的能力。这将通过
鼓励开展和传播针对NIH优先事项的高影响力多学科研究
预防新的艾滋病毒感染(预防),降低艾滋病毒感染者的发病率(治疗),
制定根除战略(无抗逆转录病毒疗法缓解)。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Judith S. Currier其他文献
Telemedicine for HIV care: a cross-sectional survey of people living with HIV receiving care at two federally qualified health centers in Los Angeles during a mature phase of the COVID-19 pandemic
- DOI:
10.1186/s12879-024-10351-x - 发表时间:
2024-12-31 - 期刊:
- 影响因子:3.000
- 作者:
Daisy Walker;Corrina Moucheraud;Derrick Butler;Christian Takayama;Steven Shoptaw;Judith S. Currier;Jay Gladstein;Risa Hoffman - 通讯作者:
Risa Hoffman
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies
ACTIV-2 中针对 COVID-19 的替沙格韦单抗/西加韦单抗或安慰剂:安全性、药代动力学以及中和抗体和抗药抗体
- DOI:
10.1016/j.isci.2025.111938 - 发表时间:
2025-03-21 - 期刊:
- 影响因子:4.100
- 作者:
Rachel A. Bender Ignacio;Kara W. Chew;Carlee Moser;Judith S. Currier;Joseph J. Eron;Arzhang Cyrus Javan;Mark J. Giganti;Justin Ritz;Michael Gibbs;Hervé Tchouakam Kouekam;Mark T. Esser;Eric S. Daar;Manish Choudhary;Rinki Deo;Courtney V. Fletcher;Jonathan Z. Li;Michael D. Hughes;Davey Smith;David Alain Wohl;for the ACTIV-2/A5401 Study Team - 通讯作者:
for the ACTIV-2/A5401 Study Team
Effects of a knowledge-based electronic patient record in adherence to practice guidelines.
基于知识的电子病历对遵守实践指南的影响。
- DOI:
- 发表时间:
1996 - 期刊:
- 影响因子:0
- 作者:
Charles Safran;David M. Rind;Roger B. Davis;D. Ives;D. Z. Sands;Judith S. Currier;W. Slack;Deborah Cotton;Makadon Hj - 通讯作者:
Makadon Hj
Willingness to trade-off years of life for an HIV cure – an experimental exploration of affective forecasting
- DOI:
10.1186/s12981-024-00640-5 - 发表时间:
2024-08-06 - 期刊:
- 影响因子:2.500
- 作者:
Ilona Fridman;Nir Eyal;Karen A. Scherr;Judith S. Currier;Kenneth A. Freedberg;Scott D. Halpern;Daniel R. Kuritzkes;Monica Magalhaes;Kathryn I. Pollak;Peter A. Ubel - 通讯作者:
Peter A. Ubel
Judith S. Currier的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Judith S. Currier', 18)}}的其他基金
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections
艾滋病毒及相关感染治疗研究艾滋病临床试验小组
- 批准号:
10812944 - 财政年份:2023
- 资助金额:
$ 300.56万 - 项目类别:
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections
艾滋病毒及相关感染治疗研究艾滋病临床试验小组
- 批准号:
10493539 - 财政年份:2022
- 资助金额:
$ 300.56万 - 项目类别:
CoVPN 3008 A Phase 3, Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
CoVPN 3008 COVID-19 mRNA 疫苗在 SARS-CoV-2 变异关注地区的 3 期、多中心、随机、功效研究
- 批准号:
10493538 - 财政年份:2022
- 资助金额:
$ 300.56万 - 项目类别:
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/
领导和运营中心(LOC)、艾滋病临床试验组(ACTG);
- 批准号:
10594377 - 财政年份:2022
- 资助金额:
$ 300.56万 - 项目类别:
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections
艾滋病毒及相关感染治疗研究艾滋病临床试验小组
- 批准号:
10395059 - 财政年份:2021
- 资助金额:
$ 300.56万 - 项目类别:
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/
领导和运营中心(LOC)、艾滋病临床试验组(ACTG);
- 批准号:
10182391 - 财政年份:2020
- 资助金额:
$ 300.56万 - 项目类别:
UCLA AIDS Prevention and Treatment Clinical Trials Unit
加州大学洛杉矶分校艾滋病预防和治疗临床试验单位
- 批准号:
10166309 - 财政年份:2020
- 资助金额:
$ 300.56万 - 项目类别:














{{item.name}}会员




